Notwithstanding positive clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial difficulty from managed care entities. Such companies are often building barriers to reimbursement, like high expense criteria and prior authorization that hinder patient access. In… Read More